The American College of Clinical Gynecology recommends consideration of brexanolone or zuranolone in postpartum patients with onset of moderate-to-severe perinatal depression in the third trimester or within 4 weeks postpartum.
Arefa Bacchus, PharmD shared key insights about the use of POMP therapy in patients with acute lymphoblastic leukemia (ALL).
Providers who are sensitive to health literacy have contributed to positive quality improvement across various institutions.
Technology and regulations can revolutionize drug manufacturing and ensure a stable supply of medications.
There are 3 PARP inhibitors that are FDA approved in multiple settings of ovarian cancer.
Mya Tran, PharmD, BCOP, offers insights for navigating the complex treatment landscape for non-small cell lung cancer.
Open to all health care professionals, the PQA meeting is a top forum for learning best practices and emerging trends in medication services, pharmacist-provided care and quality improvement initiatives.
However, comprehensive policy and payment structures are needed to ensure care sustainability.
Pharmacists can promote prevention through the implementation of antimicrobial stewardship initiatives and advocate for fecal microbiota transplant.
Fellows tap into a network of experts, their practice sites, and countless tools they can apply immediately.
Tacrolimus is a selective calcineurin inhibitor that exerts inhibitory effects on T-cell proliferation.
In this episode, Jill Simonian and Codi Peterson explore the evolving role of pharmacists in medical cannabis, addressing legal complexities, patient counseling, and key considerations for safe and effective use.
Artificial intelligence holds immense potential to address the rising demand for oncology services and improve patient outcomes by facilitating more effective, efficient, personalized cancer care.
Panelists discuss how the initiation of statin therapy requires careful consideration of contraindications and patient-specific factors, particularly in those with liver disease, renal impairment, or advanced age, while noting evolving treatment patterns toward more intensive low-density lipoprotein cholesterol (LDL-C)–lowering therapies based on individualized risk assessment.
During a time of staff shortages and increasing stress, the need to have an efficient workflow is of vital importance.
Pharmacists play an important role in managing patients with this complex condition.
The FDA reviews NDAs and BLAs to approve medications for sale and marketing in the US with decisions required by the PDUFA date.
Although RSV has long been associated with infants and young children, research demonstrates that it is also a significant health risk for adults over the age of 60.
Trilaciclib is the first FDA-approved therapy in its class to help protect bone marrow cells from damage caused by chemotherapy.
The high acceptance rates of these interventions demonstrate the key role in optimizing patient care that clinical oncology pharmacists with access to medical records play.
It’s imperative to redefine the future of pharmacy to help ensure a robust pipeline of future pharmacists and create a culture that helps ensure pharmacists live their purpose and passion.
The case study of the medical mission in Peru serves as a poignant example of the indispensable role clinical pharmacists play in health care teams, especially in challenging and resource-limited environments.
Panelists discuss how digital health technologies revolutionize women’s health care through telehealth, mobile apps, and remote monitoring, expanding access, personalization, and proactive medical support.
Available pharmacological therapies have shown high efficacy in achieving weight loss.
There are common symptoms experienced in the workplace that may be linked to hormones instead of stress.
Yet, physicians and advanced practice practitioners may have a limited understanding of the scope of an ambulatory pharmacy clinic and the value a clinical pharmacist can provide.
While progress is being made to advance the Cures Act, it is essential to ensure pharmacy interoperability given pharmacy’s critical role in health care.
By decade’s end, approval of additional bispecifics is expected for hematological malignancies, solid tumors, and non-oncology conditions such as inflammatory, autoimmune, neurodegenerative and vascular diseases, and ocular disorders and infections.